Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment

被引:687
作者
Budhu, Anuradha
Forgues, Marshonna
Ye, Qing-Hai
Jia, Hu-Liong
He, Ping
Zanetti, Krista A.
Kammula, Udai S.
Chen, Yidong
Qin, Lun-Xiu
Tang, Zhao-You [1 ]
Wang, Xin Wei
机构
[1] NCI, Liver Carcinogenesis Sect, Human Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Fudan Univ, Liver Canc Inst, Shanghai 200032, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Shanghai 200032, Peoples R China
[4] US FDA, Ctr Biol Evaluat & Res, Div Hematol, Bethesda, MD 20892 USA
[5] NCI, Mol Genet & Carcinogenesis Sect, Human Carcinogenesis Lab, Bethesda, MD 20892 USA
[6] NCI, Canc Prevent Fellowship Program, Div Canc Prevent, Bethesda, MD 20892 USA
[7] Natl Human Genome Res Inst, Canc Genet Lab, Bethesda, MD 20892 USA
[8] NCI, Surg Branch, Bethesda, MD 20892 USA
关键词
D O I
10.1016/j.ccr.2006.06.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatocellular carcinoma (HCC) is an aggressive malignancy mainly due to metastases or postsurgical recurrence. We postulate that metastases are influenced by the liver microenvironment. Here, we show that a unique inflammation/immune response-related signature is associated with noncancerous hepatic tissues from metastatic HCC patients. This signature is principally different from that of the tumor. A global Th1/Th2-like cytokine shift in the venous metastasis-associated liver microenvironment coincides with elevated expression of macrophage colony-stimulating factor (CSF1). Moreover, a refined 17 gene signature was validated as a superior predictor of HCC venous metastases in an independent cohort, when compared to other clinical prognostic parameters. We suggest that a predominant humoral cytokine profile occurs in the metastatic liver milieu and that a shift toward anti-inflammatory/immune-suppressive responses may promote HCC metastases.
引用
收藏
页码:99 / 111
页数:13
相关论文
共 41 条
[1]   P53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells [J].
Ambs, S ;
Merriam, WG ;
Ogunfusika, MO ;
Bennett, WP ;
Ishibe, N ;
Hussain, SP ;
Tzeng, EE ;
Geller, DA ;
Billiar, TR ;
Harris, CC .
NATURE MEDICINE, 1998, 4 (12) :1371-1376
[2]   Peripheral blood immunological parameters for use as markers of pre-invasive to invasive colorectal cancer [J].
Berghella, AM ;
Contasta, I ;
Pellegrini, P ;
Del Beato, T ;
Adorno, D .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2002, 17 (01) :43-50
[3]   Metastasis genes: A progression puzzle [J].
Bernards, R ;
Weinberg, RA .
NATURE, 2002, 418 (6900) :823-823
[4]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[5]   Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma [J].
D'Arrigo, A ;
Belluco, C ;
Ambrosi, A ;
Digito, M ;
Esposito, G ;
Bertola, A ;
Fabris, M ;
Nofrate, V ;
Mammano, E ;
Leon, A ;
Nitti, D ;
Lise, M .
INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (02) :256-262
[6]   Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells [J].
Dave, SS ;
Wright, G ;
Tan, B ;
Rosenwald, A ;
Gascoyne, RD ;
Chan, WC ;
Fisher, RI ;
Braziel, RM ;
Rimsza, LM ;
Grogan, TM ;
Miller, TP ;
LeBlanc, M ;
Greiner, TC ;
Weisenburger, DD ;
Lynch, JC ;
Vose, J ;
Armitage, JO ;
Smeland, EB ;
Kvaloy, S ;
Holte, H ;
Delabie, J ;
Connors, JM ;
Lansdorp, PM ;
Ouyang, Q ;
Lister, TA ;
Davies, AJ ;
Norton, AJ ;
Muller-Hermelink, HK ;
Ott, G ;
Campo, E ;
Montserrat, E ;
Wilson, WH ;
Jaffe, ES ;
Simon, R ;
Yang, LM ;
Powell, J ;
Zhao, H ;
Goldschmidt, N ;
Chiorazzi, M ;
Staudt, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (21) :2159-2169
[7]   The interplay between innate and adaptive immunity regulates cancer development [J].
de Visser, KE ;
Coussens, LM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (11) :1143-1152
[8]   Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population [J].
Fidler, IJ ;
Kripke, ML .
NATURE GENETICS, 2003, 34 (01) :23-23
[9]   MODULATION OF THE ORGAN MICROENVIRONMENT FOR TREATMENT OF CANCER METASTASIS [J].
FIDLER, IJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (21) :1588-1592
[10]   Natural killer cells: Primary target for hepatitis C virus immune evasion strategies? [J].
Golden-Mason, L ;
Rosen, HR .
LIVER TRANSPLANTATION, 2006, 12 (03) :363-372